| | |
CUSIP No. 532403201 | | Page 17 of 23 |
SCHEDULE 13D
Item 1. Security and Issuer
This Schedule 13D relates to the common stock (the “Common Stock”), par value $0.0001 per share, of Lilis Energy, Inc., a Nevada corporation (the “Issuer”). The Issuer has its principal executive offices at 201 Main Street, Suite 700, Fort Worth, TX 76102.
This Amendment No. 9 (“Amendment No. 9”) amends and supplements the Schedule 13D filed by the Reporting Persons on May 8, 2017, as amended by Amendment No. 1 to Schedule 13D filed by the Reporting Persons on July 14, 2017, as amended by Amendment No. 2 to Schedule 13D filed by the Reporting Persons on August 12, 2017, as amended by Amendment No. 3 to Schedule 13D filed by the Reporting Persons on November 17, 2017, as amended by Amendment No. 4 to Schedule 13D filed by the Reporting Persons on January 8, 2018, as amended by Amendment No. 5 to Schedule 13D filed by the Reporting Persons on February 2, 2018, as amended by Amendment No. 6 to Schedule 13D filed by the Reporting Persons on October 16, 2018, as amended by Amendment No. 7 to Schedule 13D filed by the Reporting Persons on December 28, 2018, and as amended by Amendment No. 8 to Schedule 13D filed by the Reporting Persons on March 29, 2019 (as so amended through this Amendment No. 9, the “Schedule 13D”).
Except as specifically provided herein, this Amendment No. 9 does not modify any of the information previously reported on the Schedule 13D. Capitalized terms used but not otherwise defined in this Amendment No. 9 shall have the meanings ascribed to them in the Schedule 13D. The filing of this Amendment No. 9 shall not be construed to be an admission by the Reporting Persons that a material change has occurred in the facts set forth in the Schedule 13D or that this Amendment No. 9 is required under Rule13d-2 of the Securities Exchange Act.
Item 2. Identity and Background
No change.
Item 3. Source and Amount of Funds or Other Consideration
No change.
Item 4. Purpose of Transaction
Item 4 of the Schedule 13D is hereby supplemented by adding the following:
The Reporting Persons are considering plans and proposals with respect to their investments in the Issuer that could result in certain of the events described in paragraphs (a) to (j) of the instructions to Item 4 of Schedule 13D. However, none of the Reporting Persons has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a)-(j) of Item 4 of Schedule 13D except as disclosed in this Schedule 13D.
Consistent with their investment intent and ongoing evaluation of their investment in the Issuer and alternatives to such investment, including a potential consolidation, acquisition or sale of assets or Common Stock, take-private, or changes to the Issuer’s capital structure, the Reporting Persons may, as deemed appropriate in light of existing circumstances, engage in communications with, without limitation, one or more equity holders of the Issuer, potential financing sources or potential financing partners, one or more officers of the Issuer and/or one or more members of the Issuer’s board of directors regarding such matters, subject to the Reporting Persons’ obligations under Section 5.7 of the Transaction Agreement (the “Transaction Agreement”), dated as of March 5, 2019 by and among the Company and certain of the Reporting Persons attached hereto as Exhibit A and incorporated by reference herein. During the course of such communications, a Reporting Person may advocate for or oppose one or more courses of action through its representation on the Issuer’s Board. In connection with the Reporting Persons’ potential entry into discussions regarding a potential transaction, the Issuer and Reporting Persons entered into a Waiver Agreement, dated December 10, 2019, pursuant to which the Issuer waived the standstill provision in Section 5.7 of the Transaction Agreement that, among other things, limited the Reporting Persons from acquiring additional securities of the issuer and prohibited certain actions by the Reporting Persons with respect to seeking to influence the Issuer and/or one or more members of the Issuer’s board of directors, subject to certain exceptions.